Novo Nordisk A/S (Novo Nordisk) operates as a global healthcare company. The company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
The company has a…
Analysis
Bargain bin
Novo Nordisk A/S falls in the bargain bin: the price is low relative to peers, but the business metrics give reason to pause. One caution: reported profits have recently run ahead of actual cash, which we track closely.
The price is fair. You pay 16.2× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 3% yearly growth; analysts expect 4%. The price, in other words, assumes less than the experts do.
The trajectory is tepid and the balance sheet is sturdy. The company scores 18/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.
What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202326
12
2023202420252026
All-time high
55
Jun 2023
All-time low
1
Mar 2026
Average rank
14
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
35
7
7
13
Price/Earnings
33
14
11
17
Price/Book
21
1
1
1
Dividend Yield
93
88
57
61
Value (overall)
51
42
7
13
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.